Evidence map›Paper›PMID 32157655›Full record

ArticleEndocrine pathology2020

Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.

Müjdat Kara, Fatma Tokat, M Necmettin Pamir, Ayça Ersen Danyeli

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Grading and staging for pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025
    Review
  2. Review
  3. The emerging role of Fusobacteria in carcinogenesis.European journal of clinical investigation · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Müjdat KaraDepartment of Endocrinology, Acibadem University School of Medicine, Istanbul, Turkey. drmujdat@hotmail.com.ORCID http://orcid.org/0000-0003-1425-2586
Fatma TokatDepartment of Pathology, Acibadem University School of Medicine, Istanbul, Turkey.
M Necmettin PamirDepartment of Neurosurgery, Acibadem University School of Medicine, Istanbul, Turkey.
Ayça Ersen DanyeliDepartment of Pathology, Acibadem University School of Medicine, Istanbul, Turkey.
Acıbadem University · TRÜsküdar University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The underlying mechanisms of aggressive pituitary neuroendocrine tumors (pitNETs) are still unclear. The p16 protein, encoded by the CDKN2A tumor suppressor gene on chromosome 9p21, is commonly reported to be lost in numerous types of cancer. For this reason, this study examined to examine the status of homozygous deletion of CDKN2A in high-risk pitNETs. Thirty-eight high-risk pitNETs (30 male, 8 female) were analyzed for CDKN2A deletion by fluorescent in situ hybridization (FISH). Demographic characteristics such as sex, patient age at operation, and sellar magnetic resonance imaging findings including tumor size and invasion status were recorded. The frequency of CDKN2A homozygous deletion by FISH was 3/38 (7.89%) in the high-risk pitNET group. All of these three cases with CDKN2A homozygous deletion were invasive densely granulated lactotroph tumors (p = 0.000). CDKN2A deletion was not correlated with patient age, sex, cavernous sinus invasion (CSI), and tumor size (p > 0.05). The Ki-67 proliferation index was significantly correlated with CDKN2A homozygous deletion (p = 0.003). The mean Ki-67 proliferation index was 10.7% in pitNETs with CDKN2A homozygous deletion and the Ki-67 proliferation index in the whole study group was 4.1%. CSI was significantly correlated with the morphofunctional tumor types including lactotroph tumor, invasive null cell tumor, and invasive gonadotroph tumor (p = 0.021). These findings suggest a close correlation between inactivation of p16 gene and invasive lactotroph tumors. Further investigations are needed to expand on the mechanism of p16 (CDKN2A) gene deletion in high-risk pitNETs.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16FemaleGene DeletionHumansMaleMiddle AgedNeuroendocrine TumorsPituitary NeoplasmsYoung AdultBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16CDKN2A deletionHigh-risk pitNETLactotroph tumorPituitary neuroendocrine tumorPituitary tumor

Identifiers

PMID32157655
OpenAlexW3012238891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.